05:14 PM EDT, 05/29/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Thursday that the US Food and Drug Administration granted orphan drug designation to BEAM-302.

The company said it is developing the drug for the treatment of an inherited genetic disorder, alpha-1 antitrypsin deficiency, by correcting the disease-causing mutations.

The orphan drug tag comes with potential benefits including tax credits for qualified clinical trials, exemption from user fees and market exclusivity for potentially seven years.